To tell or not to tell: Negotiating disclosure for people living with HIV on antiretroviral treatment in a South African setting

Abstract

Disclosure of HIV status occurs for a variety of reasons and in various contexts, such as to sexual partners to enable safer sexual choices, to health-care workers to access treatment and care services and to family and community members to gain various forms of support. The reasons for disclosure or non-disclosure are shaped by the relationships, needs and circumstances of people living with HIV (PLHIV) at the time of disclosure. The purpose of this study was to investigate and describe the act and experience of disclosure in order to understand how these experiences of disclosure impact on the lives of PLHIV on antiretroviral (ARV) treatment and influence adherence to treatment. Using a qualitative research design, I conducted an ethnographic study at and through the referral clinic at the Tygerberg Hospital in Cape Town, South Africa. Ninety-three adult patients (75 women) participated in the study, 32 of whom were visited at home to conduct semi-structured in-depth interviews, and 61 of them participated in a cross-sectional study at the referral clinic using researcher-administered questionnaires. A general inductive approach was used to analyse the data. Participants in both arms of the study disclosed mainly to family members, then partners and then to friends and other persons; only five had not disclosed to anyone at all. In deciding to disclose or not, the author began to see how patients negotiated their disclosure. From weighing up other people's reactions, to being concerned about the effect of their disclosure on their disclosure targets, to concealing one's status to evade untoward negative reactions towards themselves. Further, negotiating one's disclosure is not only about to whom or how to disclose, it also means finding good opportunities to disclose or conceiving ways of hiding one's status and/or medication from others in order to enhance access and adherence to their ARV treatment. Perceived rather than actual stigma played an important role in decisions not to disclose. Nonetheless, HIV remains a highly stigmatising disease. The author suggests that both the gains in support and the evasion of negative reactions from the disclosure will continue to drive negotiation of disclosure of one's status in order for patients to access and remain adherent to their treatment. Thus, areas of disclosure and concealment as they influence one's adherence to treatment need to be investigated further to facilitate adherence to treatment.Keywords: stigma, discrimination, social, household, family, partners RésuméLe partage du statut VIH a lieu pour diverses raisons et dans des contextes divers: avec les partenaires sexuels pour permettre des choix à moindre risque, avec les agents de santé pour accéder aux traitements et aux services de soins, et avec des membres de la famille et de la communauté pour obtenir diverses formes de soutien. Les motifs du partage ou du non-partage sont façonnés par les relations, les besoins et les circonstances des personnes vivant avec le VIH (PVVIH) au moment où elle...

The Role of Relationship Dynamics and Gender Inequalities As Barriers to HIV-Serostatus Disclosure: Qualitative Study among Women and Men Living with HIV in Durban, South Africa

“…This expectation is not feasible for many men and women living with HIV infection. Our findings suggest a need for approaches with attention to gender and relationship dynamics, with particular attention to the fear, mistrust, and misunderstandings of serodiscordance surrounding disclosure (11–13, 18, 20, 25, 36). …”

The Role of HIV Stigma in ART Adherence and Quality of Life Among Rural Women Living with HIV in India

“…Stigma and discrimination has also been found associated with a decreased willingness to disclose one’s HIV status, which in turn may lead to depression and anxiety (2, 24–27). Stigma and discrimination in health care settings lead to PLWH hiding their HIV status from providers (8, 27, 28), creating a primary barrier to HIV testing (7, 12, 29, 30) and care-seeking (7, 10, 31). A meta-analysis of global studies published between 1996 and 2013 found that people who had experienced HIV-related stigma were at greater risk of depression, lower social support, and “were 21% less likely to access or use health and social services” (32).…”

Early antiretroviral therapy initiation in west Africa has no adverse social consequences

“…[5]. K65R was evaluated by OLA in 2014 and pyrosequencing was performed on enrollment plasma from those with subsequent virologic treatment failure in 2006 [4].…”

“…Pathways linking ART initiation to repercussion on various social dimensions are complex and partially understood. ART initiation is associated with HIV status disclosure to relatives [4][5][6], which in turn not only lead to increased social support, but also to rejection [7,8]. Similarly, the impact of ARTon stigma and discrimination seems ambiguous [9][10][11].…”